ID   K562 BZQR
AC   CVCL_B502
SY   K562BZQR; BZQR
DR   Wikidata; Q54899292
RX   PubMed=7646550;
RX   PubMed=11416159;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:90193; NSC-224070 (BZQ; 2,5-bis(2-hydroxyethylamino)-3,6-diaziridinyl-1,4-benzoquinone).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): PubMed=11416159
ST   Amelogenin: X
ST   D18S51: 16
ST   D21S11: 29,30
ST   D8S1179: 12
ST   FGA: 21,24
ST   TH01: 9.3
ST   vWA: 16
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 21
//
RX   PubMed=7646550; DOI=10.1016/0006-2952(95)00155-S;
RA   Ward T.H., Haran M.S., Whittaker D., Watson A.J., Howard T.D.,
RA   Butler J.;
RT   "Cross-resistance studies on two K562 sublines resistant to
RT   diaziridinylbenzoquinones.";
RL   Biochem. Pharmacol. 50:459-464(1995).
//
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
//